ArticleLancet regional health. Americas2026
The Brazilian Genome Map Oncology Subproject: a nationwide multicentre hospital-based whole-genome sequencing study of breast, prostate, and colorectal cancer.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
47 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Brazilian Genome Map Oncology Subproject (BGMO) integrates paired germline and tumour WGS with lifestyle assessment across Brazil. We aimed to describe clinical, lifestyle, and genomic characteristics of probands with breast, prostate, and colorectal cancers and cascade-testing results in relatives. Methods: We conducted a cross-sectional analysis of 275 unrelated adults with breast (BC), prostate (PC), or colorectal cancer (CRC) across nine centres. Paired blood-tumour WGS was performed, and pathogenic/likely pathogenic (P/LP) germline variants were assessed using a 106-gene virtual panel. Somatic oncogenic/likely oncogenic variants were classified by tier. Lifestyle exposures before diagnosis were recorded with a questionnaire. First- and second-degree relatives of probands with P/LP variants in cancer-susceptibility genes were invited for targeted testing. Findings: The cohort included 140 BC (50.9%), 65 PC (23.6%), and 70 CRC (25.5%). Overall, 174 (63.3%) participants were women; mean age at diagnosis was 58.4 years (range 29-87). Most self-identified as brown (58.9%), followed by white (29.8%) and black (9.5%). Thirty-three probands (12.0%) carried P/LP germline variants, including 26 (9.5%) in cancer-susceptibility genes. Fifty relatives from 26 families underwent targeted testing; 19 (38.0%) carried the familial variant. Somatic WGS was successful in 269 probands; 88 tumours harboured 91 Tier 1 variants. Interpretation: This multicentre hospital-based WGS study provides an early snapshot of germline, somatic, lifestyle, and familial genetic findings in three high-burden cancers in Brazil and supports expansion to larger, longitudinal BGMO phases. Funding: Brazilian Ministry of Health (PROADI-SUS programme).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.